MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the sale of
common shares, net of...
$43,282K
Proceed from the
exercise of common stock...
$1,004K
Net cash provided by
financing activities
$43,876K
Canceled cashflow
$410K
Net increase
(decrease) in cash and cash...
$12,622K
Canceled cashflow
$31,254K
Deferred financing
costs, net
$400K
Principal payments on
finance lease...
$10K
Share-based compensation
$3,846K
Deposits
-$1,308K
Accounts payable
$535K
Non-cash lease expense
$82K
Depreciation
$43K
Maturities and sales of
marketable securities
$57,126K
Net cash used in
operating activities
-$29,062K
Net cash provided by
(used in) investing...
-$2,192K
Canceled cashflow
$5,814K
Canceled cashflow
$57,126K
Interest income
$1,669K
Net loss
-$32,766K
Purchase of marketable
securities
$59,278K
Canceled cashflow
$1,669K
Amortization of discounts on
marketable securities
$942K
Accrued liabilities
-$892K
Prepaid expenses and
other assets
$254K
Amounts receivable
$22K
Purchase of property and
equipment
$40K
Operating loss
-$34,397K
Income tax expense
$28K
Other expense, net
$10K
Total operating
expenses, excluding...
$30,551K
Total share-based
compensation
$3,846K
General And
Administrative Expense
$2,526K
Research And Development
Expense
$1,320K
Back
Back
Cash Flow
source: myfinsight.com
DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. (DMAC)